ClinicalTrials.gg

Program

foralumab

Also written as “Foralumab”, “Foralumab TZLS-401 100 µg” and “Intranasal Foralumab Solution”.

Its studies are mostly in Multiple Sclerosis, Chronic Progressive · Crohn Disease · Multiple Sclerosis · COVID-19 · Non-alcoholic Fatty Liver Disease, led by 2 companies.

Furthest: phase 2, since Aug 21, 20178 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tiziana Life Sciences61 open or runningphase 2since Aug 21, 2017Aug 21, 2017none ahead
Light Chain Bioscience - Novimmune20 open or runningphase 2since Feb 28, 2008Feb 28, 2008none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 28, 2008First study: phase 2 study in Moderate to Severe Crohn's DiseaseNew to Light Chain Bioscience - NovimmuneLight Chain Bioscience - Novimmune · NCT00630643 · 40 enrolled
  2. Dec 8, 2008Phase 2 study in Acute Renal Transplant RejectionLight Chain Bioscience - Novimmune · NCT00805909 · 12 enrolled · France
  3. Aug 21, 2017Tiziana Life Sciences's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Tiziana Life SciencesTiziana Life Sciences · NCT03291249
  4. Jul 14, 2021Phase 2 study in COVID-19Tiziana Life Sciences · NCT04983446
  5. Aug 24, 20212 phase 1 studiesTiziana Life Sciences · NCT05028946, NCT05029609
  6. Feb 2, 2024Phase 2 study in Multiple Sclerosis, Chronic ProgressiveTiziana Life Sciences · NCT06292923 · 54 enrolled · United States
  7. Feb 12, 2025Phase 2 study in Multiple SclerosisTiziana Life Sciences · NCT06890923 · 55 planned · United States

TargetBeta

CD3E →read by rule
“A monoclonal antibody directed against cluster of differentiation 3 (CD3) epsilon, with immunomodulatory activity”NCIt, by rule
“T cell surface glycoprotein CD3 inhibitor”ChEMBL 37, by rule

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
cevostamabHoffmann-La Rochephase 38
ramantamigJohnson & Johnsonphase 37
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06890923Multiple Sclerosis · United States2RecruitingTiziana Life SciencesApr 30, 202655
NCT06292923Multiple Sclerosis, Chronic Progressive · United States2CompletedTiziana Life SciencesSep 17, 202654
NCT05029609Multiple Sclerosis, Chronic Progressive1WithdrawnTiziana Life SciencesNov 20220
NCT05028946Crohn Disease1WithdrawnTiziana Life SciencesJul 7, 20230
NCT04983446COVID-192WithdrawnTiziana Life SciencesOct 30, 20220
NCT03291249Non-alcoholic Fatty Liver Disease2WithdrawnTiziana Life SciencesDec 1, 20180
NCT00805909Acute Renal Transplant Rejection · France2CompletedLight Chain Bioscience - NovimmuneJan 200912
NCT00630643Moderate to Severe Crohn's Disease2CompletedLight Chain Bioscience - NovimmuneDec 200740

How it is read

Names in the registry

  • “Foralumab”, 4 entries
  • “Foralumab TZLS-401 100 µg”, 1 entry
  • “Intranasal Foralumab Solution”, 1 entry
  • “NI-0401”, 1 entry
  • “NI-0401 (anti-CD3 mAB)”, 1 entry

Codes read as this program: TZLS401.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.